- Home
- CDNA vs PFN Comparison
CDNA vs PFN Comparison
Compare CDNA & PFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- PFN
- Stock Information
- Founded
- CDNA 1998
- PFN 2004
- Country
- CDNA United States
- PFN United States
- Employees
- CDNA N/A
- PFN N/A
- Industry
- CDNA Medical Specialities
- PFN Finance/Investors Services
- Sector
- CDNA Health Care
- PFN Finance
- Exchange
- CDNA Nasdaq
- PFN Nasdaq
- Market Cap
- CDNA 712.2M
- PFN 692.7M
- IPO Year
- CDNA 2014
- PFN N/A
- Fundamental
- Price
- CDNA $11.84
- PFN $7.51
- Analyst Decision
- CDNA Buy
- PFN
- Analyst Count
- CDNA 6
- PFN 0
- Target Price
- CDNA $27.67
- PFN N/A
- AVG Volume (30 Days)
- CDNA 1.5M
- PFN 331.7K
- Earning Date
- CDNA 08-06-2025
- PFN 01-01-0001
- Dividend Yield
- CDNA N/A
- PFN 11.66%
- EPS Growth
- CDNA N/A
- PFN N/A
- EPS
- CDNA 1.00
- PFN N/A
- Revenue
- CDNA $340,826,000.00
- PFN N/A
- Revenue This Year
- CDNA $12.81
- PFN N/A
- Revenue Next Year
- CDNA $13.36
- PFN N/A
- P/E Ratio
- CDNA $11.87
- PFN N/A
- Revenue Growth
- CDNA 14.72
- PFN N/A
- 52 Week Low
- CDNA $10.96
- PFN $5.94
- 52 Week High
- CDNA $34.84
- PFN $7.58
- Technical
- Relative Strength Index (RSI)
- CDNA 33.98
- PFN 51.39
- Support Level
- CDNA $11.73
- PFN $7.49
- Resistance Level
- CDNA $12.76
- PFN $7.57
- Average True Range (ATR)
- CDNA 0.64
- PFN 0.05
- MACD
- CDNA 0.13
- PFN -0.01
- Stochastic Oscillator
- CDNA 28.61
- PFN 25.00
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
About PFN PIMCO Income Strategy Fund II
PIMCO Income Strategy Fund II is a closed-ended fixed income mutual fund. The company's primary investment objective is to seek high current income, consistent with the preservation of capital. The fund invests in a range of securities, such as corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, municipal bonds and notes, short-term instruments, sovereign Issues, preferred Securities and others.